Review of inflammatory biomarkers in hospitalized adults with suspected infection
Abstract
Quantitative measurement of inflammatory biomarkers is frequently obtained in evaluating hospitalized patients with suspected or confirmed infections and other inflammatory disorders. These markers may be used to establish a diagnosis or assess response to therapy. Consensus on which marker to use and when to use them is not settled nor is the extent of how these indicators improve outcomes or quality of care. The following is a brief review of the common inflammatory biomarkers and a suggested approach for their utilization.
Downloads
References
Bitik B, Mercan R, Tufan A, et al. Differential diagnosis of elevated erythrocyte sedimentation rate and C-reactive protein levels: a rheumatology perspective. Eur J Rheumatol 2015; 4:131-4
Visser M, Bouter LM, McQuillan GM, et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999; 282 (22): 2131-2135.
Silvestre J, Coelho L, Povoa P. Impact of fulminant hepatic failure in C-reactive protein. J Crit Care 2010; 25: e 7-12.
Woloshin S, Schwartz L. Distribution of C-reactive protein values in the United States. N Engl J Med 352; 15:1611-1613
Wenner M, Daum P, McQuillan G. The influence of age, sex, and race on the upper reference limit of serum C-reactive protein concentration. J Rheumatol 2000; 27(10):2351.
Kushner I. Acute phase reactants. Up-to-date 2015 Jul15
Felman M, Aziz B, Kang G, et al. C-reactive protein and erythrocyte sedimentation rate discordance: frequency and causes in adults. Translational Research 2013; 161:37-43.
Harrison M. Australian Prescriber 2015; 38:93-4.
Christ-Crain M, Muller B. Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J 2007; 30:556-73.
Chu D, Mehta A, Walkey A. Practice Patterns and Outcomes Associated with Procalcitonin Use in Critically Ill patients with Sepsis. Clin Inf Dis 2017; 64: 1509-1514.
Eagye K, Kuti J, Nicolau D Risk factors and outcomes associated with isolation of meropenem high-level-resistant Pseudomonas aeruginosa. Infect Control Hosp Epidemiol 2009; 30: 746-752.
Layios N, Lambermont B, Canivet J, et al. Procalcitonin usefulness for the initiation of antibiotic treatment in intensive care unit patients. Crit Care Med 2012; 40 (8): 2304-2309.
Uzzan B, Cohen R, Nocolas P, et al. Procalcitonin as a diagnostic test for sepsis in critically ill adults after surgery or trauma: A systematic review and meta-analysis. Crit Care Med 2006; 34: 1996-2003.
Grange S, Buchonnet G, Besneir E, et al. The use of ferritin to identify critically ill patients with secondary hemophagocytic lymphohistiocytosis. Crit Care Med 2016; 44 (11): e1045-1053
Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet/Infection 2017; 17:1-13
Huang D, Yealy D, Filbin M, et al. Procalcitonin-guided use of antibiotics for lower respiratory infection. NEJM 2018; 379: 236-49.
Matthews CK, Weston VC, Jones A, et al. Bacterial septic arthritis in adults. Lancet 2010; 375:846-855
Ernst A, Weiss S, Trach L, et al. Usefulness of CRP and ESR in predicting septic joints. South Med Journal 2010; 103: 522-526
Shen CJ, Wu MS, Lin KH, et al. The use of procalcitonin in the diagnosis of bone and joint infection: a systemic review and meta-analysis. Eur J Clin Microbiol Infect Dis 2013; 32:807-814
Jenkins T, Haukoos J, Cotton E, et al. Time course of C - reactive protein and procalcitonin levels during the treatment of acute bacterial skin infections. OFID; Downloaded from https://academic.oup.com/ofid/article. 03 April 2018
